Table 6.
Correlation between NLR/CD34 and clinicopathological features in prostate cancer
| Patients and tumor characteristics | NLR/CD34 | Standard Deviation |
P-value | |||
|---|---|---|---|---|---|---|
| NLRLow/CD34Low | NLRLow/CD34High | NLRHigh/CD34Low | NLRHigh/CD34High | |||
| PSA level (ng/ml) | ||||||
| < 10 | 8 (42.1) | 1 (5.3) | 5 (26.3) | 5 (26.3) | 0.169 | 0.011 |
| 10 ~ 20 | 10 (34.5) | 6 (20.7) | 4 (13.8) | 9 (31.0) | 0.142 | |
| > 20 | 3 (11.1) | 4 (14.8) | 6 (22.2) | 14 (51.9) | 0.050 | |
| Gleason score | ||||||
| ≤ 6 | 6 (42.9) | 3 (21.4) | 3 (21.4) | 2 (14.3) | 0.227 | 0.005 |
| 7 | 11 (39.3) | 2 (7.1) | 8 (28.6) | 7 (25.0) | 0.161 | |
| 8 ~ 10 | 4 (12.1) | 6 (18.2) | 4 (12.1) | 19 (57.6) | 0.059 | |
| T stage | ||||||
| T1–2 | 15 (45.5) | 4 (12.1) | 7 (21.2) | 7 (21.2) | 0.196 | 0.018 |
| T3–4 | 6 (14.3) | 7 (16.7) | 8 (19.0) | 21 (50.0) | 0.084 | |
| Lymph node metastasis | ||||||
| N0 | 18 (39.1) | 8 (17.4) | 11 (23.9) | 9 (19.6) | 0.201 | 0.011 |
| N1 | 3 (10.3) | 3 (10.3) | 4 (13.8) | 19 (65.6) | 0.173 | |
| Distant metastasis | ||||||
| M0 | 16 (37.2) | 9 (20.9) | 7 (16.3) | 11 (25.6) | 0.282 | 0.029 |
| M1 | 5 (15.6) | 2 (6.3) | 8 (25.0) | 17 (53.1) | 0.186 | |
| TNM stage | ||||||
| Stage II | 19 (73.1) | 2 (7.7) | 2 (7.7) | 3 (11.5) | 0.195 | 0.000 |
| Stage III ~ IV | 2 (4.1) | 9 (18.4) | 13 (26.5) | 25 (51.0) | 0.067 | |
NLR neutrophil-to-lymphocyte ratio, PSA prostate specific antigen